Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Mainz Biomed to be renamed Quantum Cyber and appoints Robert P. Liscouski as chairman

Mainz Biomed announces a strategic reorientation: the company will change its name to Quantum Cyber and will use the NASDAQ ticker symbol QUCY starting Thursday. Robert P. Liscouski has been appointed chairman of the board; the measures are to take effect at an extraordinary general meeting in April. The reorientation follows ongoing financial difficulties, with a share price of $0.83, a market capitalization of $8.93 million and a weak Financial Health Score, while the company plans to continue developing its pancreatic screening offering and to evaluate other assets. » More on de.investing.com

Financials

In the last quarter, Mainz Biomed B.V. had revenue of €853.57k and net profit of -€4.75m

(EUR)	September 2026	YoY
Revenue	853.57k	700.20%
Gross profit	82.63k	3.13%
Net profit	-4.75m	41.75%
EBITDA	-4.34m	92.54%

Fundamentals

Metric	Value
Market capitalization	€13.07m
Number of shares	22.77m
52-week high/low	€4.43 - €0.27
Dividends	No
Beta	2.43
P/E ratio	-0.42
PEG ratio	0.01
P/B ratio	2.50
P/S ratio	13.20

Company profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Name	Mainz Biomed B.V.
CEO	David Elliot Lazar
Headquarters	Mainz, Germany
Website	mainzbiomed.com
Sector	Health Care
Industry	Biotechnology
IPO	05/11/2021
Employees	13